Ad agency nabs two new accounts, one from M&C Saatchi
bcg2 Healthcare has nabbed an account from M&C Saatchi without a pitch.
It’s scored the business for the launch of Avigra (pronounced “a-vee-gra”), the new brand for Pfizer’s little blue pill that’ll compete against a raft of expected generic brand competitors.
The launch is set for
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Hazel Phillips
Tue, 03 May 2011
Tue, 03 May 2011
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Ad agency nabs two new accounts, one from M&C Saatchi
14280